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Elevated homocysteine levels and low vitamin B
12
and folate levels have been associated with deteriorated bone health. This
systematic literature review with dose-response meta-analyses summarizes the available scientific evidence on associations of
vitamin B
12
, folate, and homocysteine status with fractures and bone mineral density (BMD). Twenty-seven eligible cross-sectional
(𝑛 = 14) and prospective (𝑛 = 13) observational studies and one RCT were identified. Meta-analysis on four prospective studies
including 7475 people showed a modest decrease in fracture risk of 4% per 50 pmol/L increase in vitamin B
12
levels, which was
borderline significant (RR = 0.96, 95% CI = 0.92 to 1.00). Meta-analysis of eight studies including 11511 people showed an increased
fracture risk of 4% per 𝜇mol/L increase in homocysteine concentration (RR = 1.04, 95% CI = 1.02 to 1.07). We could not draw a
conclusion regarding folate levels and fracture risk, as too few studies investigated this association.Meta-analyses regarding vitamin
B
12
, folate and homocysteine levels, and BMD were possible in female populations only and showed no associations. Results from
studies regarding BMD that could not be included in the meta-analyses were not univocal.
1. Introduction
Osteoporosis is a chronic, multifactorial disorder which
is characterized by low bone mass and microarchitectural
deterioration of bone tissue [1]. Its major consequence is
fractures. Especially hip fractures are frequently associated
with institutionalization and increased mortality, and thus
with an increased social and economic burden. This burden
is expected to increase substantially in Europe in the coming
decades due to a rise in life expectancy [2].
Elevated homocysteine concentrations and low vitamin
B
12
and folate status have been associated in several studies
with lower bone mineral density (BMD) and higher fracture
risk in elderly [3–11].
An elevated plasma homocysteine level (>15 𝜇mol/L) is
prevalent in 30–50% of people older than 60 years [12–14].
The cause is multifactorial; a combination of environmental
and genetic factors, nutrition, lifestyle, and hormonal factors
[15]. Vitamin B
12
and folate are major determinants of
homocysteine metabolism [16, 17] and supplementation with
vitamin B
12
and folic acid has been shown to be effective in
normalizing homocysteine levels [18, 19]. Reversing elevated
homocysteine levels through folic acid and vitamin B
12
supplementation could theoretically prevent the problem of
impaired bone health and osteoporosis. However, at present,
no consensus is reached on the magnitude of the association
between vitamin B
12
, folate, homocysteine, and bone health
nor on the possible effect of vitamin B
12
and folate supple-
mentation on bone health.
Up until now one systematic review including a meta-
analysis summarized the evidence on homocysteine and
fracture risk, showing that higher homocysteine levels signif-
icantly increase the risk of fracture [20]. No meta-analyses
are known on the topic of folate and vitamin B
12
in relation
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to bone health. The purpose of this review is to provide
a systematic overview, where possible including pooled
estimates of the dose-response association, of the scientific
evidence available from randomized controlled trials (RCTs),
prospective cohort, and cross-sectional studies addressing
vitamin B
12
, folate, and homocysteine levels in association
with bone health, that is, fracture risk and BMD, in adults
and elderly people.
2. Methods
This systematic review with dose-response meta-analyses
was conducted within the scope of the EURRECA (Euro-
pean Micronutrient Recommendations Aligned) Network
of Excellence (http://www.eurreca.org/) [21]. We followed a
standardizedmethodology which is described in short below.
2.1. Search Strategy and Selection of Articles. We conducted
systematic literature searches for (1) vitamin B
12
, (2) folate,
and (3) homocysteine. The electronic databases MEDLINE,
EMBASE, and Cochrane Library Central were searched,
using search terms in “MeSH” terms and “title” and “abstract”
on study designs in humans, vitamin B
12
, folate, homocys-
teine, and intake or status. The full Medline search strategy is
available online, (see Appendix 1 in Supplementary Material
at http://dx.doi.org/10.1155/2013/486186).
To be able to use the same search to identify publications
on other health related outcomes both in adults and elderly
and in younger population groups, no terms were added
to limit the search to health outcome or study population.
Moreover, by using a broad search we expected a more
complete retrieval of relevant publications. In this review only
the results on vitamin B
12
, folate, and homocysteine status
(i.e., biomarkers measured in serum or plasma) in relation to
bone health indicators (fracture risk andBMD) are presented.
In addition to the search, reference lists of 10 review articles
were checked to identify potentially relevant references that
were not identified with the multidatabase search.The search
was not limited by language. This review contains studies up
to July 2012.
We selected articles in two steps. The first selection step
included screening for title and abstract by three independent
investigators (J. P. van Wijngaarden, E. L. Doets, SB). In
the second selection step, full texts of the selected abstracts
were evaluated on basis of predefined inclusion criteria by
four investigators (J. P. van Wijngaarden, E. L. Doets, A.
Szczecińska, MP).
For the purpose of alignment and quality control 10%
of the references in each selection step was screened and
selected in duplicate by two investigators independently.
Results were compared and discrepancies were resolved by
unanimous consensus among all investigators.
Studies were eligible for inclusion if they were conducted
in apparently healthy human subjects aged ≥18 y. Further-
more, studies had to report fracture incidence, fracture risk,
or bone mineral density (BMD) as a health outcome and had
to report baseline data on the outcome measure.
Observational studies were included if they (1) had a
prospective cohort, nested case-control, or cross-sectional
design, and (2) addressed serum/plasma concentration of





, methylmalonic acid (MMA), holotranscobalamin
(holoTC)), folate status (serum/plasma folate or erythrocyte
folate), or homocysteine status (serum/plasma homocys-
teine). Intervention studies were included if they (1) had a
randomized controlled trial design, (2) studied the effects
of vitamin B
12
or folic acid supplements, fortified foods or
micronutrient intake from natural food sources and included
a placebo or untreated comparison group, and (3) had a
minimum intervention duration of six months.
2.2. Data Extraction and Statistical Analysis. We extracted
data for each of the identified studies on population char-
acteristics, study design, assessment of vitamin B
12
, folate
and homocysteine status, and fracture risk or bone mineral
density.
Opportunities for meta-analysis were evaluated based on
comparability of health outcome and status marker. If less
than three comparable studies were available, results were
qualitatively described. If three or more comparable studies
were available, the results of these individual studies were
expressed in a standardized format to allow comparison
in the form of a continuous dose-response meta-analysis
that pools the regression coefficient (𝛽) (SE) from multiple
adjusted models. We chose to express association measures
for serum/plasma vitamin B
12
per 50 pmol/L. When 𝛽s were
not reported in the original article, we transformed Relative
Risk (RR), Hazard Ratio (HR), or Odds Ratio (OR) to 𝛽s,
using a standardized method [22]. The transformations to
obtain 𝛽s and SEs and statistical analyses were performed
using R statistics version 2.9.2 (http://www.R-project.org/),
with statistical significance defined as 𝑃 < 0.05. HR and OR
were considered as RR because the outcome was relatively
rare. If articles reported insufficient data (missing data,
inconsistencies, or any other uncertainties), we contacted
corresponding authors for additional information.
We calculated summary estimates of comparable studies
using random effects meta-analysis. Applying themethods of
DerSimonian and Laird, the between study variance was esti-
mated which was used to modify the weights for calculating
the summary estimate [23]. Residual heterogeneity between
studies was evaluated using 𝑄-statistic and 𝐼2-statistic.
In total, from 3 searches we identified 11837 potentially
relevant articles, of which 9835 articles were excluded based
on title and abstract. Of the remaining 2002 articles, 1961
articles were excluded based on full texts, leaving 41 articles.
As the searches were partly overlapping and some articles
addressed more than one association this resulted in 20
unique articles, 19 observational and 1 intervention. A search
update on July 2nd, 2012 resulted in an additional 8 obser-
vational studies, which makes a total of 28 included articles.
All addressed the association between vitamin B
12
, folate or
homocysteine status, and fracture risk or BMD. The flow
diagram of the process of screening and selection is shown
in Figure 1.
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. Four longitudinal observational studies
[3, 24–26], including 7475 elderly people with 3 to 16 years of
follow-up and a total of 458 cases addressed the association
between serum/plasma vitamin B
12
and fracture (Table 1).
Pooled analysis of the association between 50 pmol/L increase
in plasma/serum B
12
and change in fracture risk showed an
inverse association (RR = 0.96, 95% CI = 0.92 to 1.00)
with no heterogeneity between studies (𝐼2 = 0%, 𝑃 =
0.76) (Figure 2). This indicates that a vitamin B
12
increase of
50 pmol/L tends to decrease the risk of fracture with 4%.
3.1.2. Folate. Three longitudinal observational studies exam-
ined the association between plasma folate and fractures
[24–26] (Table 2). One study showed that women, but not
men, with plasma folate in the lowest quartile had a higher
fracture risk (HR 2.40, 95% CI 1.50 to 3.84) compared to
the highest (reference) quartile (𝑃 for trend <0.001) [24].
Ravaglia et al. (2005) [26] showed a significant association
between low folate status and fracture risk when folate was
analyzed as a dichotomous variable (lowest quartile of folate
status versus other 3 quartiles), but when analyzed as a
continuous variable, no significant association was observed
[26]. One study did not observe an association [25].
3.1.3. Homocysteine. Eleven longitudinal observational stud-
ies examined the association between homocysteine status
and fracture incidence [3–5, 25–29] (Table 3). A meta-
analysis of eight studies, including 11511 elderly people with
3 to 12.6 years of follow-up and 1353 cases, showed a
significantly increased fracture risk with increasing plasma
homocysteine (𝜇mol/L) (summary estimate RR 1.04, (95%
CI: 1.02 to 1.07). Heterogeneity between studies was large
(𝐼2 = 60.6%, 𝑃 = 0.0002) (Figure 3). When hip fractures
4 Journal of Nutrition and Metabolism
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Figure 2: Forest plot of the association between vitamin B
12
(50 pmol/L) and risk of fracture: Meta-Analysis of 4 observational studies.
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Figure 3: Forest plot of the association between homocysteine and risk of fracture: Meta-Analysis of 8 observational studies.
(3 studies; [24, 28, 29]) and total fractures (5 studies; [3, 26,
27, 30, 31]) were analyzed separately, the relation remained
significant, 1.06 (95% CI: 1.03 to 1.08, 𝐼2 = 0%, 𝑃 = 0.72) and
1.04 (95% CI: 1.00 to 1.08, 𝐼2 = 65.0%, 𝑃 = 0.011).
Three studies that were not included in the meta-analysis
also showed significant associations between homocysteine
levels and fracture risk. These studies were not included
because the necessary data could not be retrieved from the
articles; either homocysteine levels were log-transformed [4,
5] or data was not shown for population homocysteine status
[25]. Regardless the type of analysis, women and men in the
highest homocysteine quartile had a 1.7 to 3.8 higher RR or
HR than those in the lowest or the lowest three quartiles
[4, 5, 25].
3.2. Bone Mineral Density. In the studies included in this
review BMD was measured at various sites in the body (e.g.,
lumbar spine, femoral neck, radius, hip, and total body).
As BMD differs per site in the body, we pooled results per
biomarker (serum/plasma vitamin B
12
, folate, and homocys-
teine) and per site for the three sites generally measured (FN,
LS, or total hip), thus resulting in 9meta-analyses. Betas of the
individual studies are shown in Tables 1, 2, and 3. The studies
included in themeta-analyses took only women into account.
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Only five studies regarding BMD included a male population
[6, 7, 10, 35, 38], and these studies were not comparable
quantitatively because differences in the presentation of
results or differences in the measured BMD sites.
3.2.1. Vitamin B
12
. Pooled analysis showed no association
between serum/plasma vitamin B
12
levels and BMD in
women; FN: 𝛽 = 0.00, 95% CI: −0.13 to 0.14, 𝐼2 = 0%,
𝑃 = 0.40 [9, 37, 40]; LS: 𝛽 = −2.25, 95% CI: −7.98 to 3.49,
𝐼
2
= 99.5%, 𝑃 < 0.0001 [9, 37, 39, 40]; total hip 𝛽 = −2.23,
95% CI: −10.38 to 5.92, 𝐼2 = 97.7%, and 𝑃 = 0.0001
[33, 37, 39, 40]. The studies that could not be included
in the meta-analyses showed diverse results; in six out of
eight studies low serum/plasma vitamin B
12
was significantly
associatedwith lowBMDat at least one site [6, 7, 11, 32, 35, 38].
Two studies did not observe an association between vitamin
B
12
status and BMD [34, 36]. Morris et al. addressed MMA
levels as well as a marker for vitamin B
12
status and observed
a lower BMD with higher serumMMA concentrations [7].
3.2.2. Folate. Pooled analysis showed no association between
serum/plasma folate and BMD in women; FN: 𝛽 = 0.00, 95%
CI: −0.03 to 0.03, 𝐼2 = 0.00%, 𝑃 = 0.88 [9, 37, 40]; LS: 𝛽 =
0.01, 95% CI: 0.00 to 0.01, 𝐼2 = 0%, 𝑃 = 0.77 [9, 37, 39, 40];
total hip: 𝛽 = 0.00, 95% CI: 0.00 to 0.01, 𝐼2 = 78.5%, 𝑃 =
0.0003 [10, 33, 37, 39, 40].
From the studies that could not be compared in a
meta-analysis, three studies showed significant associations
between folate status and BMD or change in BMD over time
[8, 10, 34]. Five studies did not observe an association between
folate status and BMD [7, 32, 36, 38, 41].
3.2.3. Homocysteine. Pooled analyses showed no association
between serum/plasma homocysteine levels and BMD in
women; FN: 𝛽 = −0.01, 95% CI: −0.04 to 0.02, 𝐼2 = 31.5%,
𝑃 = 0.21 [9, 27, 37, 40]; LS: 𝛽 = −0.01, 95% CI: −0.08 to
0.05, 𝐼2 = 98.4%, 𝑃 < 0.0001 [9, 27, 37, 39, 40]; total hip:
𝛽 = −0.03, 95% CI: −0.08 to 0.02, 𝐼2 = 99.9%, 𝑃 < 0.0001
[10, 27, 33, 37, 39, 40]. The studies that could not be pooled
showed diverse results. In five studies a high homocysteine
level was significantly associated with low BMD or change in
BMD over time at at least one site [7, 29, 31, 32, 41]. Three
studies did not observe a significant association between
homocysteine status and BMD or change in BMD [8, 34, 36].
3.3. Intervention Studies. Up until now, only one RCT (𝑁 =
47) which met our inclusion criteria studied the efficacy of
B-vitamin supplementation on BMD [42]. This study shows
some evidence that BMD may be increased with high doses
of B-vitamin supplementation in people with hyperhomocys-
teinemia (tHcy> 15𝜇mol/L).However, this outcomewas only
found in a subanalysis of 8 hyperhomocysteinemic subjects
[42].
4. Discussion
Our meta-analyses showed a significant association of
homocysteine levels with fracture risk and a weak though
significant inverse association of vitamin B
12
levels with
fracture risk. We could not draw a conclusion regarding
folate levels and fracture risk, as too few studies investigated
this association. Meta-analyses regarding vitamin B
12
, folate
and homocysteine levels and BMD in women found no
associations. Results from studies regarding BMD that could
not be included in the meta-analyses are not univocal.
To our knowledge this systematic review with meta-
analyses is the most extensive systematic review on the
association of vitamin B
12
, folate and homocysteine with
bone health until now. Previous non-systematic literature
reviews on the association between folate, vitamin B
12
, and
homocysteine with bone health reported similar results, that
is, conflicting evidence with suggestions towards the asso-
ciation of homocysteine levels with fracture [43–45]. These
reviews did not report a systematic literature search strategy
and did not provide a quantitative cumulative result. In our
review the most recent published articles have been taken
into account.The search strategy we used was systematic and
extensive, andwe usedwell-defined in- and exclusion criteria.
One recent systematic review included ameta-analysis on
the association between tHcy and fractures [20]. This meta-
analysis is different in design than ours, as it is not a dose-
response meta-analysis. To overcome the variation in cut-off
levels for low vitamin B
12
and folate status and high homocys-
teine status, and to allow comparison and subsequent combi-
nation of individual studies in the performed meta-analyses,
we expressed results of individual studies in a standardized
format. We assumed a linear, continuous dose-response
association between markers of vitamin B
12
and folate with
fracture rather than a threshold effect. This assumption is
generally used in meta-analyses. Furthermore, in some of the
key articles addressing the association of homocysteine levels
with fractures this association is present [4, 5].
A common concern in meta-analyses is heterogeneity
between studies. In our meta-analyses we experienced var-
ious levels of statistical heterogeneity (no heterogeneity to
large heterogeneity). The heterogeneity may be explained
by the differences in mean age of the study populations
(41–78 years), differences in mean status of vitamin B
12
(190–549 pmol/L), folate (5.2–24.9 nmol/L) and homocys-
teine (9.3–16.5 𝜇mol/L), differences in sex distribution of the
study populations, duration of follow-up (3–16 years), and
level of adjustment for confounders. Althoughmost included
studies adjusted for a wide range of confounders for fracture
risk or BMD, residual confounding by other unmeasured
or inadequately measured factors cannot be ruled out. For
example, low vitamin D status is a risk factor for fracture
[46]. From the studies included in our meta-analyses for
fracture three out of nine adjusted for vitamin D status [24,
25, 27]. Outcomes do not seem to differ between studies
that corrected for vitamin D status and studies that did not.
Homocysteine levels are increased with renal dysfunction,
often measured by serum or urine creatinine levels. Five out
of eight studies in the meta-analysis regarding homocysteine
and fracture risk corrected for creatinine levels [3, 24, 26, 27,
29], and outcomes did not seem to differ.
As almost all studies were performed in countries without
mandatory folate fortification or were performed before
16 Journal of Nutrition and Metabolism
the fortification era in the USA and Australia, we do not
consider folate fortification as a source of heterogeneity in our
analyses.
The majority of studies included were longitudinal and
cross-sectional observational studies. We could only include
one intervention study, which had a very small study pop-
ulation (𝑁 = 47). One intervention study which found
a beneficial effect of vitamin B
12
and folic acid supple-
mentation on fracture risk could not be included in our
systematic review, because this study investigated a pop-
ulation of hemiplegic patients following stroke [47]. The
generalizability of these findings is confined to a highly
selective patient population with a high percentage of vita-
min D deficiency and a high fracture risk. As evidence
from intervention studies is lacking, currently no causal
effect between vitamin B
12
, folate and homocysteine levels
and bone health can be established. Consequently, it is
yet unknown whether extra vitamin B
12
and folate intake
through supplementation could reverse the observed nega-
tive effects of vitamin B
12
and folate deficiency and elevated
homocysteine levels. Further evidence from an interven-
tion study is expected soon, as a large intervention study
on the effect of vitamin B
12
and folic acid supplemen-
tation on fracture risk, BMD, and bone turnover mark-
ers is currently carried out with results expected in 2013
[48].
As the quality of included studies determines the quality
of the review andmeta-analysis, we assessed the overall risk of
bias of each individual study using standardized procedures
largely based on guidance from the Cochrane Collaboration
[49], resulting in one of the following judgments: low,
moderate, or high risk of bias. Twenty out of the 28 included
studies were evaluated as having moderate (𝑛 = 15) or high
risk (𝑛 = 5) of bias. These studies did take one or more of
the predefined confounders into account, that is, age, sex,
smoking, physical activity, and body weight, or the study was
funded or cofunded by a commercial organization.Due to the
limited number of studies included in the meta-analyses, we
were not able to study the effect of the overall risk of bias, nor
of its single components on the pooled effect measures.There
seems to be no difference in the outcomes of studies with low
risk of bias compared to studies withmoderate or high risk of
bias, and we therefore assume that the quality of the included
studies had no effect on the outcome of this review.
The intake of folate and vitamin B
12
are a determinant
of folate, vitamin B
12
, and homocysteine status. To deal with
potential malabsorption of vitamin B
12
[50] and reduced
bioavailability of folate [51], the use of biomarkers for vitamin
B
12
and folate status is preferred over measures of intake
when studying associations with bone health in elderly
people.
In studies addressing folate status, serum or plasma
folate was measured, which is considered as an appropriate
marker for folate status in epidemiological studies [52].
Homocysteine is a nonspecific marker for both folate and
vitamin B
12
status [53], which makes it a relevant biomarker
in this review. Regarding the metabolic interactions between
vitamin B
12
, folate, and homocysteine combined with the
variety in data presented in the studies, we were not able
to investigate the possibility that a low vitamin B
12
or folate
status in combination with a high homocysteine level might
result in a higher fracture risk in comparison to a low vitamin
B
12
or folate status or homocysteine level alone. In most
studies regarding vitamin B
12
status, status was assessed with
serum or plasma vitamin B
12
. Other, more sensitive markers
for vitamin B
12
deficiency, like MMA and HoloTC [54], were
addressed only in a few studies. We could therefore not draw
conclusions about the association between these biomarkers
and outcomes on bone health.
There are several suggested mechanisms for the associ-
ation between vitamin B
12
, folate, homocysteine, and bone
health. Homocysteine may interfere with collagen cross-
linking. Cross-links are important for the stability and
strength of the collagen network. Interference in cross-link
formation would cause an altered bone matrix, resulting
in more fragile bones [55]. As collagen cross-links do not
alter BMD, this may explain why a more convincing result
is found regarding fractures than BMD, as suggested for
example by Van Meurs et al. [5]. Vitamin B
12
deficiency
has been associated with impaired functional maturation of
osteoblasts [56]. Some in vitro studies support the hypothesis
of a possible favorable effect of vitamin B
12
supplementation,
although results are equivocal. Vitamin B
12
has been shown
to stimulate osteoblast proliferation and alkaline phosphatase
activity [57] but Herrmann et al. were not able to show
any significant and consistent effect of vitamin B
12
or folic
acid on osteoblast activity [58]. Recent publications show
evidence of osteoclast stimulation in the presence of high





and folate are not the only B-vitamins involved
in the homocysteine metabolism. Various micronutrients,





choline also affect homocysteine levels [16, 17, 62], and may
consequently affect bone health. Given that vitamin B
12
and
folate are the main factors influencing homocysteine levels,
and therefore the primary focus in a homocysteine lowering




Considerations for Future Research and Conclusions. The
mechanisms involved in the association between biomark-
ers of B-vitamins and bone health are still unclear and
therefore more fundamental research is required to estab-
lish the potential mechanisms. Subsequently, both observa-
tional and intervention studies should preferably not focus
on just one biomarker in relation to the homocysteine
metabolism, but take a biomarker profile into account,
including serum/plasma vitamin B
12
, MMA, HoloTC, folate,
and homocysteine levels. Evidence is needed from well-
designed, large intervention studies to establish a causal rela-
tionship between markers of B-vitamins and bone health.
This systematic review with meta-analyses shows that
elevated homocysteine levels are associated with increased
fracture risk. Vitamin B
12
status may be associated with
fracture risk and evidence for an association between folate
status and fracture risk is scarce. Vitamin B
12
, folate, and
homocysteine levels are probably not associated with BMD,
but results are not univocal.
Journal of Nutrition and Metabolism 17
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